Entinostat (MS-275)

Catalog No.S1053

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Entinostat (MS-275) Chemical Structure

Entinostat (MS-275) Chemical Structure
Molecular Weight: 376.41

Validation & Quality Control

Cited by 61 publications:

14 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Entinostat (MS-275) is available in the following compound libraries:

HDAC Inhibitors with Unique Features

Product Information

  • Compare HDAC Inhibitors
    Compare HDAC Products
  • Research Area

Product Description

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
IC50 0.51 μM 1.7 μM
In vitro MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3NWnKe3ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmS3TWM2OD1yLkC2NUDPxE1?NXzkfHZJW0GQR1XS
ALL-PONF3xT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPIVXhKSzVyPUCuNFY{PTVizszNNFT4TpdUSU6JRWK=
697NWfI[JlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTBwMEm5O|Yh|ryPMlTGV2FPT0WU
NCI-H748NYPS[IlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkS2TWM2OD1yLkGwN|M1KM7:TR?=M1vzfnNCVkeHUh?=
NKM-1MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMUC5NVIh|ryPMo\5V2FPT0WU
ES1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnSNndqUUN3ME2wMlEyOjV3IN88US=>MXjTRW5ITVJ?
NCI-H1963MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jSTWlEPTB;MD6xNVU4QSEQvF2=M2T5RXNCVkeHUh?=
NCI-H1417NHjFWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTBwMUK5O|Qh|ryPNHLmSJpUSU6JRWK=
NEC8MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXwco9GUUN3ME2wMlE{PTJ5IN88US=>MWjTRW5ITVJ?
CRO-AP2M4K0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXGOYtKSzVyPUCuNVY5QDlizszNM2HOOXNCVkeHUh?=
A3-KAWNWTRZXRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLIc|FKSzVyPUCuNVc3OjdizszNMn3XV2FPT0WU
SF539NGDqVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjETWM2OD1yLkG5OVk{KM7:TR?=MkDpV2FPT0WU
NOS-1MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zZemlEPTB;MD6xPVYyQSEQvF2=MUjTRW5ITVJ?
NTERA-S-cl-D1M1fZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XHemlEPTB;MD6yNFEyOyEQvF2=MkDBV2FPT0WU
COR-L88MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHNbohFUUN3ME2wMlIzQTV7IN88US=>M3noOXNCVkeHUh?=
EM-2M3;Ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\wTlRKSzVyPUCuNlQxPzlizszNMVfTRW5ITVJ?
KARPAS-45M1zhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{L5[mlEPTB;MD6yO|g{OyEQvF2=M3vqbnNCVkeHUh?=
DSH1M1PYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTBwMki3NFgh|ryPM3H6e3NCVkeHUh?=
HT-144M2XlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTBwM{CyOVYh|ryPNWG3e5U5W0GQR1XS
ATN-1NXPuZpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LOR2lEPTB;MD6zNFU4PiEQvF2=MnLYV2FPT0WU
HELNXTNblVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\KPWlEPTB;MD6zNVM1QCEQvF2=NWSwblU2W0GQR1XS
NB12NV\GWHhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTBwM{G3OVYh|ryPMV3TRW5ITVJ?
LU-139NFHydGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjlTWM2OD1yLkOzOVEh|ryPMkLnV2FPT0WU
J-RT3-T3-5NV3NUYNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nvVGlEPTB;MD6zN|cyPiEQvF2=MkDlV2FPT0WU
MOLT-13Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jNbWlEPTB;MD6zN|gyKM7:TR?=NXjieoMzW0GQR1XS
SRM1LKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTBwM{SyOlEh|ryPMmn5V2FPT0WU
CMKMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;ZcGlEPTB;MD6zOVczPyEQvF2=M1rKc3NCVkeHUh?=
ES8MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDtOY1vUUN3ME2wMlM3ODJ{IN88US=>MlmyV2FPT0WU
LB647-SCLCNGn5SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jabWlEPTB;MD6zOlc{KM7:TR?=NGTwcHhUSU6JRWK=
TE-8MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwM{[5N|Uh|ryPMkLYV2FPT0WU
BV-173NFi2dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjYeIVLUUN3ME2wMlM4OTJzIN88US=>MWPTRW5ITVJ?
DELM2LHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDkTWM2OD1yLkO3OFg4KM7:TR?=NFPIU|FUSU6JRWK=
ARH-77Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwM{ixPVMh|ryPMWPTRW5ITVJ?
NCCITM{TpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXzTWM2OD1yLkO4OlQ6KM7:TR?=NGrveHBUSU6JRWK=
RPMI-8402M2HyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzxT4pKSzVyPUCuN|g4ODFizszNM3nsXHNCVkeHUh?=
MONO-MAC-6NWnzUnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XzSGlEPTB;MD6zPFc4PiEQvF2=NHzweJJUSU6JRWK=
SK-MM-2MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TveGlEPTB;MD6zPVg3QCEQvF2=MlLLV2FPT0WU
CHP-126NEHU[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPRTWM2OD1yLkSwNlMyKM7:TR?=MUHTRW5ITVJ?
A101DNHPRSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvOZmZKSzVyPUCuOFA{KM7:TR?=M{THSnNCVkeHUh?=
SCHNGW0V3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmSyTWM2OD1yLkSwN|QzKM7:TR?=MYLTRW5ITVJ?
NMC-G1NIiwfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkK5TWM2OD1yLkSwN|Y4KM7:TR?=M2jYN3NCVkeHUh?=
NCI-H209NVLjO4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrGS|ZOUUN3ME2wMlQxPjF|IN88US=>NGjtUnZUSU6JRWK=
MOLT-16NVrVTW9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XwWWlEPTB;MD60NVAyPyEQvF2=NE\RcldUSU6JRWK=
RPMI-6666MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjGPJZZUUN3ME2wMlQyOTJizszNM{jRb3NCVkeHUh?=
OPM-2M{fnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTPd2VKSzVyPUCuOFE2OTNizszNNH:yPVlUSU6JRWK=
MRK-nu-1NWXUNHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nXWWlEPTB;MD60N|E2OyEQvF2=Mo[4V2FPT0WU
BC-1NV3EXmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTBwNEO0NFMh|ryPMnTEV2FPT0WU
MHH-NB-11NIe2dY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{mwR2lEPTB;MD60N|Q2OyEQvF2=Mnq0V2FPT0WU
Ramos-2G6-4C10NIfrO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTBwNEO4PVch|ryPNH7KW3RUSU6JRWK=
LS-513NFLi[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXielkyUUN3ME2wMlQ1PTBzIN88US=>MonsV2FPT0WU
K5M4P2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnRTWM2OD1yLkS3NFI2KM7:TR?=MX;TRW5ITVJ?
HOP-62NHHsfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwNEizOVgh|ryPM3u3WnNCVkeHUh?=
NCI-H187NXr4RnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnpeVVyUUN3ME2wMlQ6OjJ5IN88US=>NGnzUFZUSU6JRWK=
BE-13Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnexTWM2OD1yLkS5OlYyKM7:TR?=MWPTRW5ITVJ?
HC-1M2LQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTBwNUC0O|Mh|ryPMlfuV2FPT0WU
ACNNYPDPZVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojxTWM2OD1yLkWxNFI5KM7:TR?=M3rRNnNCVkeHUh?=
HCC1599MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1OzNGlEPTB;MD61NVU4KM7:TR?=NHK2eVFUSU6JRWK=
MV-4-11NH72U5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHhc5NKSzVyPUCuOVMxPDFizszNMYXTRW5ITVJ?
LC-2-adNVGzS3QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mli4TWM2OD1yLkWzOlY{KM7:TR?=MV;TRW5ITVJ?
HL-60MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Pld2lEPTB;MD61OFI3OSEQvF2=MkLHV2FPT0WU
NB17NXjUO|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTBwNUSzPEDPxE1?MUDTRW5ITVJ?
TE-1MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jV[WlEPTB;MD61OVMxPiEQvF2=MoC0V2FPT0WU
NCI-H524M2LpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvNTWM2OD1yLkW1OFAyKM7:TR?=NHjMOGdUSU6JRWK=
MZ7-melMmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrFTWM2OD1yLkW2NVA2KM7:TR?=NVXDelJsW0GQR1XS
L-363M13hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFqzXo1KSzVyPUCuOVY3PTdizszNNE\zTnZUSU6JRWK=
BL-41MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3yzZWlEPTB;MD61Olg5QSEQvF2=M3;ROHNCVkeHUh?=
LU-134-AMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTBwNUewO|Mh|ryPMXrTRW5ITVJ?
SIG-M5MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTBwNUe4OFgh|ryPMmn6V2FPT0WU
ONS-76MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlv1TWM2OD1yLkW4NlQzKM7:TR?=M13UZnNCVkeHUh?=
KARPAS-299MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE[yc2hKSzVyPUCuOVg2ODRizszNMlznV2FPT0WU
DU-4475MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmL6TWM2OD1yLkW4O|A{KM7:TR?=M3PIbnNCVkeHUh?=
NB69NF;ZSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTBwNUm4NlUh|ryPM1mw[nNCVkeHUh?=
MHH-PREB-1M4LzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTBwNkC3NVkh|ryPNEHJZpBUSU6JRWK=
LU-165NF7UemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTBwNkG4NVIh|ryPMlWyV2FPT0WU
LOUCYNIPYZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTBwNkOzOlQh|ryPNXHtO5BmW0GQR1XS
NCI-H526MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLBfY1RUUN3ME2wMlY{PTRzIN88US=>M2jNbXNCVkeHUh?=
KE-37NITxVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2xfnNiUUN3ME2wMlY1Ojd4IN88US=>NXv5OWJpW0GQR1XS
NALM-6NYnUbVM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfZTWM2OD1yLk[0PFYh|ryPM2nlS3NCVkeHUh?=
CW-2NFzINWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTPO5VKSzVyPUCuOlU4QTRizszNMWDTRW5ITVJ?
SU-DHL-1NIjNXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYT6O2hmUUN3ME2wMlY2QTR5IN88US=>MmDZV2FPT0WU
NB13NWPqTlRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFflZXlKSzVyPUCuOlY5OTdizszNMn\rV2FPT0WU
QIMR-WILMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIqzNlBKSzVyPUCuOlg{PDNizszNNWrTdYRSW0GQR1XS
ECC12M2\sR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1q5NWlEPTB;MD63NFA5PiEQvF2=M3q2UXNCVkeHUh?=
KALS-1NYLWPZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwN{C0PVIh|ryPM2fxS3NCVkeHUh?=
COR-L279M{H5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTBwN{C5PVYh|ryPM4rSUHNCVkeHUh?=
NB14M1X4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;HfmlEPTB;MD63NlYyPyEQvF2=NFy5T4JUSU6JRWK=
CCRF-CEMNHnuWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwN{S2OlEh|ryPMVfTRW5ITVJ?
SW954M2fSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjhZVFKSzVyPUCuO|U6QTlizszNNIP6TYVUSU6JRWK=
IST-SL1NHTCXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3RSWxKSzVyPUCuO|c{PDhizszNMkjHV2FPT0WU
LAMA-84MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\vTWM2OD1yLke3OVY4KM7:TR?=MXXTRW5ITVJ?
DaudiMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7j[|BKSzVyPUCuO|c3QDFizszNM17v[HNCVkeHUh?=
BC-3M4WxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH62dXJKSzVyPUCuO|g{ODhizszNNXXuTndUW0GQR1XS
HCC2998Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPPdmtFUUN3ME2wMlc5OzZizszNMoLSV2FPT0WU
NCI-H69NFnlelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnJPYtLUUN3ME2wMlgxOTR5IN88US=>MlXiV2FPT0WU
CPC-NNXr2WnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwOEC1NlQh|ryPMkLsV2FPT0WU
NOMO-1M4jTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfjT5NlUUN3ME2wMlgyODh2IN88US=>M1GyUnNCVkeHUh?=
CESSMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYD3RY5VUUN3ME2wMlgyOTl5IN88US=>NIPRSFhUSU6JRWK=
LC4-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTBwOESwNFch|ryPMV;TRW5ITVJ?
BL-70M3n3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwOEW3NFIh|ryPMmfHV2FPT0WU
ES4NGqwfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIS0U3hKSzVyPUCuPFU5PjhizszNNELE[I9USU6JRWK=
HCE-TMlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHlTWM2OD1yLki3NVcyKM7:TR?=NX7PTWpxW0GQR1XS
JARMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NECzU5FKSzVyPUCuPFc5OjdizszNMVPTRW5ITVJ?
ST486NGTKNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u0S2lEPTB;MD64O|kyPyEQvF2=MkC0V2FPT0WU
KS-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXLTplRUUN3ME2wMlg5ODl4IN88US=>MUfTRW5ITVJ?
GDM-1M3q2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\nUmZKSzVyPUCuPFg3QDdizszNMUHTRW5ITVJ?
EHEBM{LaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGP3bHdKSzVyPUCuPVI2QDVizszNMUTTRW5ITVJ?
LB2518-MELMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LZfGlEPTB;MD65N|I5PCEQvF2=Mlq3V2FPT0WU
GOTONYPvOXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nl[GlEPTB;MD65OVA4PiEQvF2=NX:1cFM5W0GQR1XS
LXF-289MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTiR41KSzVyPUCuPVU6ODFizszNMlq1V2FPT0WU
ES6MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTBwOU[0N|ch|ryPMnz5V2FPT0WU
OS-RC-2MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7GTGhKSzVyPUCuPVY5OyEQvF2=NGrBcWVUSU6JRWK=
DMS-153M3fmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLwTWM2OD1yLkm3OFY6KM7:TR?=NU\nVJJRW0GQR1XS
SK-PN-DWMn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYmySnJYUUN3ME2wMlk4QDNzIN88US=>MnvTV2FPT0WU
HHNX3N[JVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDaZ3R6UUN3ME2wMlk5QTV7IN88US=>M2Dn[nNCVkeHUh?=
SH-4NF71dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPrTWM2OD1zLkCyOFEh|ryPM1LJSnNCVkeHUh?=
MOLT-4MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjSTWM2OD1zLkCzOFU1KM7:TR?=M4Xxe3NCVkeHUh?=
TGWMl6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnL5TWM2OD1zLkC3Olc2KM7:TR?=NXXU[IFXW0GQR1XS
L-540M4jrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrMTWM2OD1zLkGwOlA1KM7:TR?=MkPDV2FPT0WU
PF-382MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33M[GlEPTB;MT6xNVUyOyEQvF2=MX\TRW5ITVJ?
LC-1FMmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXT5ZmJwUUN3ME2xMlEzODB5IN88US=>Mn;ZV2FPT0WU
OVCAR-4MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzxOHBIUUN3ME2xMlE{OTZ3IN88US=>NWP6fGdWW0GQR1XS
A4-FukM1HOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrpZnVKSzVyPUGuNVU{PjRizszNNYnWdY1IW0GQR1XS
HCC2218NXrRUnNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTFwMU[2OFEh|ryPNGHsZZVUSU6JRWK=
HAL-01NUmwepFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFwMU[5OFMh|ryPMn\1V2FPT0WU
IST-MEL1NIX4XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEH3WXBKSzVyPUGuNVc3PTlizszNM{SxVXNCVkeHUh?=
NCI-H719NILTWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTFVXVPUUN3ME2xMlE4QDl6IN88US=>MUTTRW5ITVJ?
EVSA-TMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrJZ5hKSzVyPUGuNVgyOTRizszNM33kSnNCVkeHUh?=
SK-NEP-1NXXaNotJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVz6T4VbUUN3ME2xMlIxOjZ4IN88US=>MU\TRW5ITVJ?
OCUB-MMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjRTWM2OD1zLkKxOFg6KM7:TR?=M2DPUHNCVkeHUh?=
MEG-01M1PiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXqcWRKSzVyPUGuNlIyOThizszNMXLTRW5ITVJ?
no-10NVHiPHVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjHRW4yUUN3ME2xMlI{OTF{IN88US=>M4HKZnNCVkeHUh?=
MHH-CALL-2MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnX2TWM2OD1zLkK0O|IyKM7:TR?=NHzvcIZUSU6JRWK=
SK-N-DZMmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPRTWM2OD1zLkK0O|c3KM7:TR?=NVX4VollW0GQR1XS
SCLC-21HNVLDWGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Xtc2lEPTB;MT6yOlQ4QCEQvF2=MUXTRW5ITVJ?
CTV-1MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrIUGRKSzVyPUGuNlc1OjVizszNMVvTRW5ITVJ?
NB1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\NRlBKSzVyPUGuNlc4OzJizszNNFTK[Y5USU6JRWK=
NCI-H64MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDwTYdKSzVyPUGuNlg1PjJizszNNXj4VJBqW0GQR1XS
MDA-MB-134-VIMli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljETWM2OD1zLkK4OVc4KM7:TR?=Moq0V2FPT0WU
LB2241-RCCMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY[5SW8yUUN3ME2xMlI5PjZ|IN88US=>NIPHUmxUSU6JRWK=
8-MG-BANXnTXWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fObmlEPTB;MT6yPFg3PiEQvF2=NFPDSFRUSU6JRWK=
LP-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTFwMkm5OFch|ryPMmHDV2FPT0WU
LS-411NM3u2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTFwM{C5PVgh|ryPMYHTRW5ITVJ?
CAL-148MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnve49KSzVyPUGuN|I2PDJizszNNXjlZ|BCW0GQR1XS
NCI-H2171MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;SS2lEPTB;MT6zOFUxOiEQvF2=NHvKNmtUSU6JRWK=
JiyoyeP-2003MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fBOmlEPTB;MT6zOVM6KM7:TR?=M1S2XnNCVkeHUh?=
NCI-H2107NELuR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\VNmlEPTB;MT6zOVg5OyEQvF2=MYnTRW5ITVJ?
BB30-HNCNETiR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTFwM{i5O|gh|ryPMYnTRW5ITVJ?
K-562NIP6fHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:2TWM2OD1zLkO5NlE6KM7:TR?=M{DXTXNCVkeHUh?=
PSN1NFq0Z41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPiTWM2OD1zLkSyNlg4KM7:TR?=MVHTRW5ITVJ?
HCC2157M1HTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljUTWM2OD1zLkSyOlkyKM7:TR?=NUfGTII3W0GQR1XS
SBC-1NXLMV5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXG1XXZqUUN3ME2xMlQzPzRzIN88US=>M{TDS3NCVkeHUh?=
MC116NIntXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnPNYp[UUN3ME2xMlQ{PjF3IN88US=>MlnLV2FPT0WU
KARPAS-422NHrwbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTFwNEWzOVgh|ryPMXfTRW5ITVJ?
LB996-RCCNE\aWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\6PWlEPTB;MT60O|ExOyEQvF2=NWGwU2RsW0GQR1XS
MSTO-211HMnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHaOnpKSzVyPUGuOFc6QDdizszNMmjvV2FPT0WU
BT-474NELU[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPXc3lCUUN3ME2xMlUyPzZ2IN88US=>NHXt[29USU6JRWK=
A388M1;5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXThWms2UUN3ME2xMlUyQTR3IN88US=>NVvwSXE2W0GQR1XS
SJSA-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\PTWM2OD1zLkWyNlYh|ryPM1z5VHNCVkeHUh?=
COLO-829M37LNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLhNpVDUUN3ME2xMlU{PTZ2IN88US=>NFOwfW1USU6JRWK=
KM-H2M2TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1q5dWlEPTB;MT61OlY4KM7:TR?=MkLxV2FPT0WU
GR-STMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\GTWM2OD1zLkW2PFIh|ryPMonXV2FPT0WU
RPMI-8866MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzFTWM2OD1zLk[wNVQ1KM7:TR?=NH:3WVVUSU6JRWK=
KG-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzTb2V3UUN3ME2xMlYyQTBzIN88US=>NHi1bmdUSU6JRWK=
NCI-H82M1WzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nwZmlEPTB;MT62N|QxPiEQvF2=NEX0cYxUSU6JRWK=
LB1047-RCCNXi4fnoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTFwNkO0OVkh|ryPM13JXXNCVkeHUh?=
KM12M4PUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPsTWM2OD1zLk[0O{DPxE1?NVXmNmRpW0GQR1XS
NB5M2XVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwNkW2O|ch|ryPNVPTN5pbW0GQR1XS
HDLM-2M4[0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTFwNkiyPFEh|ryPMkHKV2FPT0WU
KU812M1Hjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1G4N2lEPTB;MT62PVYxPSEQvF2=MVHTRW5ITVJ?
DBMm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfJbFZKSzVyPUGuO|A{PTNizszNM{P3WHNCVkeHUh?=
HD-MY-ZMmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zOfGlEPTB;MT63OVI{PCEQvF2=MkXDV2FPT0WU
KURAMOCHIMlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPIZnlKSzVyPUGuO|czODdizszNM3vHd3NCVkeHUh?=
ETK-1NVPn[FFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjvUpV6UUN3ME2xMlc5QDd7IN88US=>NV\KN29lW0GQR1XS
SK-UT-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnLPFhOUUN3ME2xMlc6Ozh6IN88US=>M1ywXnNCVkeHUh?=
HUTU-80M3nNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTFwN{m1NFgh|ryPNFH5TGdUSU6JRWK=
ES7M3fkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfkTWM2OD1zLkiwN|AzKM7:TR?=M4rLcnNCVkeHUh?=
SW872M3ToUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFL2Z5lKSzVyPUGuPFE{QTVizszNMV;TRW5ITVJ?
TK10M1TWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrvbZpKSzVyPUGuPFMyODhizszNMnf6V2FPT0WU
LB831-BLCMof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYK1OVdMUUN3ME2xMlg{PTZ|IN88US=>NVvvN5VTW0GQR1XS
TE-9MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DkbmlEPTB;MT64OFQzOiEQvF2=MnvrV2FPT0WU
MLMAM2P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnJTWM2OD1zLki4NlM1KM7:TR?=NILaUHZUSU6JRWK=
D-542MGNUnIcJBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\WdYFKSzVyPUGuPFk{PzNizszNNWHYe2JnW0GQR1XS
EW-16MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTFwOUK3NkDPxE1?MYTTRW5ITVJ?
LOXIMVINGPDeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTFwOUOyPEDPxE1?MnfiV2FPT0WU
GB-1NHzwSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTFwOUO4OlYh|ryPMmj6V2FPT0WU
IST-SL2NED5Z25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXf6c|d3UUN3ME2yMlAxOjZ{IN88US=>MmHOV2FPT0WU
LAN-6MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\wTWM2OD1{LkCxPVY3KM7:TR?=M1\aXHNCVkeHUh?=
NCI-H510ANHXYeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTJwMES1NFIh|ryPM33lRXNCVkeHUh?=
NCI-H1092NWPI[lVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\lUGNKSzVyPUKuNFUyOjRizszNMWjTRW5ITVJ?
HTNHzWWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXWS492UUN3ME2yMlExPDV2IN88US=>NFL2b25USU6JRWK=
RL95-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NISyT25KSzVyPUKuNVE1QDJizszNNH;TcVJUSU6JRWK=
NCI-H1355Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nS[mlEPTB;Mj6xNVc6OiEQvF2=NHrGOnhUSU6JRWK=
NCI-H720M37ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofOTWM2OD1{LkG2PFc{KM7:TR?=NIT1UGJUSU6JRWK=
NCI-H1522MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml76TWM2OD1{LkKxO|I{KM7:TR?=M{\k[nNCVkeHUh?=
LB373-MEL-DM1vORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jFO2lEPTB;Mj6yOlkxOiEQvF2=NUPvS|BwW0GQR1XS
DG-75NYrjNm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnRPXdKSzVyPUKuNlcyPDhizszNMVvTRW5ITVJ?
ML-2NFLpXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDNTWM2OD1{LkOyPFU2KM7:TR?=NIm0WGRUSU6JRWK=
SF126MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnqTWM2OD1{LkOzNFk1KM7:TR?=NX7BcGR5W0GQR1XS
MPP-89NGPQRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXKNmF3UUN3ME2yMlM{OTR3IN88US=>M1;KeHNCVkeHUh?=
NCI-H345NYPDZ5VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXUU3NOUUN3ME2yMlM{Ojd5IN88US=>MVfTRW5ITVJ?
LS-123NYnaS2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTJwM{S5N|Yh|ryPMWnTRW5ITVJ?
NB10NHLO[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTRTWM2OD1{LkSxNFkzKM7:TR?=NEHYS|BUSU6JRWK=
CGTH-W-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fsNmlEPTB;Mj60NlI3PyEQvF2=MmrmV2FPT0WU
CP66-MELMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTJwNEe3O{DPxE1?M3Tvd3NCVkeHUh?=
L-428M{L6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7iTHVKSzVyPUKuOFg2OjFizszNMXjTRW5ITVJ?
DMS-79MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nDfmlEPTB;Mj61OFExOyEQvF2=M{fzZnNCVkeHUh?=
NCI-H1882M2nocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\4XG1KSzVyPUKuOlc2PjJizszNNVLaZXhPW0GQR1XS
KGNM3fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTzcZFKSzVyPUKuO|Y5PzZizszNNIPvOIFUSU6JRWK=
EW-1NU\VWGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrkXYFKSzVyPUKuO|cxQDNizszNMnHMV2FPT0WU
U-266NX\1XWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzKWIU1UUN3ME2yMlg1QDJ|IN88US=>M1r5OHNCVkeHUh?=
COLO-320-HSRNGjOTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G5UWlEPTB;Mj64OVY1OSEQvF2=Mo\PV2FPT0WU
KMOE-2NGK4SmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{e4R2lEPTB;Mj64O|cyOSEQvF2=NXn6fJMyW0GQR1XS
BB49-HNCNVLrO257T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFT5cYNKSzVyPUKuPVI1QCEQvF2=NG\0fFZUSU6JRWK=
GI-1NIOwVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIm2NJZKSzVyPUKuPVI6PTdizszNMUDTRW5ITVJ?
NCI-H1304NVrtdIRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3JWIhKSzVyPUOuNFA2OTFizszNMX7TRW5ITVJ?
NCI-H2227NHfZZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rwV2lEPTB;Mz6wNlA4QSEQvF2=M{faTnNCVkeHUh?=
U-87-MGNF\JZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PxWmlEPTB;Mz6wN|UyOyEQvF2=MW\TRW5ITVJ?
NCI-H747M4fxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPxTWM2OD1|LkC1NlA3KM7:TR?=M2ezdXNCVkeHUh?=
CTB-1NYS0Xo1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4foRmlEPTB;Mz6wOVM4PiEQvF2=NIXjOGxUSU6JRWK=
RPMI-8226M3;sdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7te2pRUUN3ME2zMlE1Ozd6IN88US=>NH7tV2lUSU6JRWK=
NCI-H2141Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\wNJdKSzVyPUOuNVY2PjZizszNNVf3PZVNW0GQR1XS
IST-MES1MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILscW5KSzVyPUOuNVgzPzlizszNMYLTRW5ITVJ?
TE-5MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7xTWM2OD1|LkKxN|QzKM7:TR?=MmXPV2FPT0WU
UACC-257MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTNwNEO2OVkh|ryPNFPhNJJUSU6JRWK=
SK-N-FIMoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWH2cWZHUUN3ME2zMlQ2OjJ5IN88US=>M1rDXnNCVkeHUh?=
MFH-inoMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLrOVBOUUN3ME2zMlQ3PTh7IN88US=>MmrBV2FPT0WU
SF268MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfYU2lKSzVyPUOuOFgyPzRizszNMV3TRW5ITVJ?
TE-12MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWW3W2M2UUN3ME2zMlUyPjl7IN88US=>MlvHV2FPT0WU
NB6NH3u[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;RcFNCUUN3ME2zMlU2PTZ|IN88US=>NFjqSFNUSU6JRWK=
DJM-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTNwNUm4PVkh|ryPNFPKbmRUSU6JRWK=
MZ1-PCNVK5ToFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEG0[WdKSzVyPUOuOlE3OjRizszNM1;QOnNCVkeHUh?=
OCI-AML2Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTNwNkK2O|Eh|ryPM1HCenNCVkeHUh?=
NCI-H1155NHjX[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TNVWlEPTB;Mz63NFk1PyEQvF2=MVTTRW5ITVJ?
RKOMlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvzeWtOUUN3ME2zMlc4OTh7IN88US=>Mkj2V2FPT0WU
ECC4MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;wb2lEPTB;Mz65O|E6PSEQvF2=M{nTNnNCVkeHUh?=
BB65-RCCNWLGSpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTNwOUe1OFch|ryPNUf4OotXW0GQR1XS
EB-3MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v6XGlEPTB;Mz65PVY{OyEQvF2=MlfMV2FPT0WU
SHP-77NXn5bWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTRwMEC1NlQh|ryPNEDs[2RUSU6JRWK=
NCI-H2196MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTRwMEW2NlUh|ryPNF;GVmRUSU6JRWK=
GI-ME-NNFLqOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TzVmlEPTB;ND6wOlM6QSEQvF2=NF7WU|ZUSU6JRWK=
MN-60NXzmZ4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELYZ4VKSzVyPUSuNVA5PyEQvF2=NWTkcplLW0GQR1XS
NCI-H1694MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTRwMUO0NFUh|ryPMVnTRW5ITVJ?
LU-65NF3sbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrjblRKSzVyPUSuNVU{OzJizszNMVnTRW5ITVJ?
NCI-H1436NILzWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPUTHhnUUN3ME20MlE5OzN|IN88US=>MX;TRW5ITVJ?
KINGS-1Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LkXGlEPTB;ND6zNVQ{OiEQvF2=NFjacpZUSU6JRWK=
GT3TKBMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml[zTWM2OD12LkOzNlY5KM7:TR?=M2rRSnNCVkeHUh?=
BeckerMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2X5S2lEPTB;ND6zO|MyOiEQvF2=MUTTRW5ITVJ?
HCC1187NGS2[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTRwOEm2OVch|ryPMVfTRW5ITVJ?
D-502MGNHqyUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnRWWhkUUN3ME21MlAxPDF4IN88US=>MkLRV2FPT0WU
VA-ES-BJMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHe0SnNKSzVyPUWuNVM4PzhizszNM4m3W3NCVkeHUh?=
NB7M4TQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTVwMUSxNVIh|ryPNVX5U4ltW0GQR1XS
SW962MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLSTWM2OD13LkO4PFE1KM7:TR?=MkntV2FPT0WU
no-11MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHRbZNRUUN3ME21Mlc3OzR|IN88US=>MVPTRW5ITVJ?
KNS-81-FDM1zVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\QRpdMUUN3ME21MlkxPjl2IN88US=>MoL6V2FPT0WU
COLO-684MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlz0TWM2OD13Lkm5OFk1KM7:TR?=NUfRdoN1W0GQR1XS
D-263MGMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLSN2tKSzVyPU[uNFg5QTVizszNMXjTRW5ITVJ?
EW-24MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XsSGlEPTB;Nj6yPFUyKM7:TR?=MmD1V2FPT0WU
TE-10Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXYTWM2OD14LkSyOlI{KM7:TR?=MVrTRW5ITVJ?
EKVXNGHpOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LqXWlEPTB;Nj60OlMzOSEQvF2=MX7TRW5ITVJ?
NCI-H1648MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTZwNke1OVch|ryPNF7FZm9USU6JRWK=
LB771-HNCNHfCUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELXT5hKSzVyPU[uPVI{ODFizszNNXjLNoZLW0GQR1XS
SK-MEL-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4S5XGlEPTB;OD6xN|E3PiEQvF2=MVXTRW5ITVJ?
COLO-668NInyRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnWzTWM2OD16LkK3O|g3KM7:TR?=NUOxZpFSW0GQR1XS
EW-12M{XySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLMbYpbUUN3ME24MlQxQDB|IN88US=>M2DOTHNCVkeHUh?=
A253NFnGfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPl[ndpUUN3ME24Mlg1PjZzIN88US=>NWPyd2FUW0GQR1XS
NCI-H2126NVvRWWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzEO5RXUUN3ME24Mlg6OzF7IN88US=>MUTTRW5ITVJ?
Calu-6MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXPTWM2OD16Lkm5NFQzKM7:TR?=NF;XelVUSU6JRWK=
NCI-H23M4LrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTlwMUe3OFYh|ryPNGPob2pUSU6JRWK=
WSU-NHLNELz[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LYZ2lEPTB;OT63O|Q4QCEQvF2=NG\qZmlUSU6JRWK=
MMAC-SFMn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTlwOUe5NFQh|ryPMVTTRW5ITVJ?
SK-LMS-1NEnFRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17nOGlEPTB;MUCuNlg{PCEQvF2=NVP2OHpQW0GQR1XS
GCIYM4WwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjHWlVJUUN3ME2xNE42QTJ2IN88US=>NWPLOFlGW0GQR1XS
TE-15NFruUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH3TWM2OD1zMT62NFA1KM7:TR?=M1LLXHNCVkeHUh?=
EoL-1-cellM2jKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXKblJnUUN3ME2xNU44Pjh{IN88US=>MYjTRW5ITVJ?
NCI-H2081MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTFzLke3PFYh|ryPNHXiWFJUSU6JRWK=
EW-3MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\weJJKSzVyPUGyMlI1PjNizszNNXS4PZE2W0GQR1XS
CAS-1NIXobHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTXXYNXUUN3ME2xNk4{PjNzIN88US=>MWPTRW5ITVJ?
C2BBe1M1H0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVL5VYJ4UUN3ME2xNk43OTNzIN88US=>NGC4NmhUSU6JRWK=
D-247MGM{XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTXNnVKSzVyPUGyMlc6PTJizszNMl3wV2FPT0WU
NCI-SNU-5MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4OwRWlEPTB;MUKuPFAyOyEQvF2=M4OwbXNCVkeHUh?=
LS-1034MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGCxclZKSzVyPUG0MlM6PzVizszNMYHTRW5ITVJ?
EW-18NGHSb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17SbmlEPTB;MUSuOFQ5KM7:TR?=NXr6S|REW0GQR1XS
RajiMnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjuR5hKSzVyPUG0MlUxPDlizszNMnXOV2FPT0WU
D-283MEDMoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fKWmlEPTB;MUSuOlI4OSEQvF2=NWr6e3BJW0GQR1XS
MZ2-MELNGDDTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnGyTWM2OD1zND65Olk3KM7:TR?=NIqyNXpUSU6JRWK=
NCI-SNU-16MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTF3LkS2N|Mh|ryPMXjTRW5ITVJ?
P30-OHKNHXqfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXSze2JGUUN3ME2xO{44QDNzIN88US=>M{XlWXNCVkeHUh?=
RXF393M4TYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmr4TWM2OD1zOT6wNVg3KM7:TR?=MUDTRW5ITVJ?
NCI-H1395MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTJyLk[3NFMh|ryPM2LydXNCVkeHUh?=
U-698-MNYDNV286T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTZUHlrUUN3ME2yNE44ODd3IN88US=>NUfYTIVYW0GQR1XS
NCI-SNU-1M{P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jZO2lEPTB;MkCuO|IzOyEQvF2=M{PReXNCVkeHUh?=
SW684NWezVFJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LJSGlEPTB;MkGuNVcyPiEQvF2=Ml3JV2FPT0WU
NCI-H716NXPTbJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTYUlhYUUN3ME2yNU4{OTV2IN88US=>NIrEdpRUSU6JRWK=
JVM-2NHvCV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPPTWM2OD1{MT60NVM{KM7:TR?=NVflN49HW0GQR1XS
NCI-H1581M2nYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHleI9EUUN3ME2yNk41OTR6IN88US=>NEfmOHNUSU6JRWK=
CA46MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4m3WmlEPTB;M{GuOlk{PiEQvF2=NFviUJBUSU6JRWK=
SNB75NETvZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DnUWlEPTB;M{OuOlUxOyEQvF2=M3vLenNCVkeHUh?=
KNS-42MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITrcFZKSzVyPUO1Mlk3OjRizszNMmP4V2FPT0WU
TURM1zGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWq4UHVPUUN3ME2zOk4xPTJzIN88US=>MlvUV2FPT0WU
REHNI\B[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;pRWlEPTB;M{euPFIyOSEQvF2=MmXwV2FPT0WU
EW-22M1HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFq5SJVKSzVyPUSyMlI5QDVizszNNHWyVZVUSU6JRWK=
NCI-H446NHq1dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPad3RZUUN3ME20Nk44QDV|IN88US=>MUfTRW5ITVJ?
ES3NXHLVnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTR|LkGzN|kh|ryPMVnTRW5ITVJ?
EW-11NIfDdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1ToZ2lEPTB;NESuPFIyQCEQvF2=MXTTRW5ITVJ?
RH-1NXOweHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHX0O|lKSzVyPUS3MlU5OTJizszNMWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]
Features

Protocol(Only for Reference)

Kinase Assay:

[6]

Standard HDAC Assays Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.

Cell Assay:

[2]

Cell lines A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
Concentrations ~ 10 μM
Incubation Time 3 days
Method

Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.

Animal Study:

[1]

Animal Models A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
Formulation Dissolved with 0.05 N HCl, 0.1% Tween 80
Dosages 12.3, 24.5 and 49 mg/kg
Administration Administered orally once daily 5 days per week for 4 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Saito A, et al. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597.

[2] Sugawara T, et al. 95th AACR, Orlando, 2004, Abst#2451

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02780804 Not yet recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplas  ...more Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) March 2017 Phase 1
NCT02833155 Not yet recruiting Breast Cancer EddingPharm Oncology Co., LTD. July 2016 Phase 1
NCT02820961 Recruiting Breast Cancer|Estrogen Receptor Positive Breast Cancer Syndax Pharmaceuticals June 2016 Phase 1
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax P  ...more Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 2016 Phase 2
NCT02708680 Not yet recruiting Breast Cancer Syndax Pharmaceuticals|Roche Pharma AG April 2016 Phase 1|Phase 2

view more

Chemical Information

Download Entinostat (MS-275) SDF
Molecular Weight (MW) 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms SNDX-275
Solubility (25°C) * In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate

Frequently Asked Questions

  • Question 1
    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

    Answer: 2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HDAC Products

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Recently Viewed Items

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us